Tempest获得临床阶段CD7靶向慢病毒体内CAR-T平台的独家授权选择权

美股速递

6 hours ago

Tempest Therapeutics Inc.（TPST）近日宣布，已成功获得一项独家选择权，旨在许可一个处于临床阶段的、靶向CD7的慢病毒体内CAR-T平台。此举标志着该公司在细胞治疗领域迈出了关键一步，有望进一步增强其在肿瘤免疫疗法方面的布局。

该平台依托慢病毒载体技术，能够实现体内CAR-T细胞的直接生成，从而可能简化传统体外细胞改造流程，并降低相关成本与复杂性。临床阶段的数据积累为平台的有效性与安全性提供了初步验证，尤其针对CD7阳性恶性肿瘤，如某些类型的白血病和淋巴瘤。

根据协议条款，Tempest有权在特定条件下行使该选择权，以获取平台的全球独家开发和商业化权益。这一战略决策不仅丰富了公司的研发管线，也为探索联合疗法及新适应症开辟了可能性。

市场分析人士指出，体内CAR-T技术是当前基因与细胞治疗领域的前沿方向，其便捷性和可扩展性备受期待。Tempest若能成功整合该平台，或将提升其在竞争激烈的肿瘤治疗市场中的地位。公司管理层表示，将对该平台进行进一步评估，并可能在未来启动相关临床试验。

此次协议的达成，反映了Tempest致力于通过创新技术平台来应对未满足医疗需求的坚定承诺。随着更多细节的披露，业界将密切关注这一潜在合作对Tempest长期价值的影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1147881183"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147881183\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147881183?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-09-16 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147881183","market":"us","top_or_hot":-1,"title":"Tempest获得临床阶段CD7靶向慢病毒体内CAR-T平台的独家授权选择权","media":"美股速递","content":"<p>Tempest Therapeutics Inc.（TPST）近日宣布，已成功获得一项独家选择权，旨在许可一个处于临床阶段的、靶向CD7的慢病毒体内CAR-T平台。此举标志着该公司在细胞治疗领域迈出了关键一步，有望进一步增强其在肿瘤免疫疗法方面的布局。</p>\n<p>该平台依托慢病毒载体技术，能够实现体内CAR-T细胞的直接生成，从而可能简化传统体外细胞改造流程，并降低相关成本与复杂性。临床阶段的数据积累为平台的有效性与安全性提供了初步验证，尤其针对CD7阳性恶性肿瘤，如某些类型的白血病和淋巴瘤。</p>\n<p>根据协议条款，Tempest有权在特定条件下行使该选择权，以获取平台的全球独家开发和商业化权益。这一战略决策不仅丰富了公司的研发管线，也为探索联合疗法及新适应症开辟了可能性。</p>\n<p>市场分析人士指出，体内CAR-T技术是当前基因与细胞治疗领域的前沿方向，其便捷性和可扩展性备受期待。Tempest若能成功整合该平台，或将提升其在竞争激烈的肿瘤治疗市场中的地位。公司管理层表示，将对该平台进行进一步评估，并可能在未来启动相关临床试验。</p>\n<p>此次协议的达成，反映了Tempest致力于通过创新技术平台来应对未满足医疗需求的坚定承诺。随着更多细节的披露，业界将密切关注这一潜在合作对Tempest长期价值的影响。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempest获得临床阶段CD7靶向慢病毒体内CAR-T平台的独家授权选择权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempest获得临床阶段CD7靶向慢病毒体内CAR-T平台的独家授权选择权\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-09-16 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tempest Therapeutics Inc.（TPST）近日宣布，已成功获得一项独家选择权，旨在许可一个处于临床阶段的、靶向CD7的慢病毒体内CAR-T平台。此举标志着该公司在细胞治疗领域迈出了关键一步，有望进一步增强其在肿瘤免疫疗法方面的布局。</p>\n<p>该平台依托慢病毒载体技术，能够实现体内CAR-T细胞的直接生成，从而可能简化传统体外细胞改造流程，并降低相关成本与复杂性。临床阶段的数据积累为平台的有效性与安全性提供了初步验证，尤其针对CD7阳性恶性肿瘤，如某些类型的白血病和淋巴瘤。</p>\n<p>根据协议条款，Tempest有权在特定条件下行使该选择权，以获取平台的全球独家开发和商业化权益。这一战略决策不仅丰富了公司的研发管线，也为探索联合疗法及新适应症开辟了可能性。</p>\n<p>市场分析人士指出，体内CAR-T技术是当前基因与细胞治疗领域的前沿方向，其便捷性和可扩展性备受期待。Tempest若能成功整合该平台，或将提升其在竞争激烈的肿瘤治疗市场中的地位。公司管理层表示，将对该平台进行进一步评估，并可能在未来启动相关临床试验。</p>\n<p>此次协议的达成，反映了Tempest致力于通过创新技术平台来应对未满足医疗需求的坚定承诺。随着更多细节的披露，业界将密切关注这一潜在合作对Tempest长期价值的影响。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TPST","symbol_name":"Tempest Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1147881183","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147881183","pubTimestamp":1789502770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tempest Therapeutics Inc.近日宣布，已成功获得一项独家选择权，旨在许可一个处于临床阶段的、靶向CD7的慢病毒体内CAR-T平台。根据协议条款，Tempest有权在特定条件下行使该选择权，以获取平台的全球独家开发和商业化权益。Tempest若能成功整合该平台，或将提升其在竞争激烈的肿瘤治疗市场中的地位。此次协议的达成，反映了Tempest致力于通过创新技术平台来应对未满足医疗需求的坚定承诺。随着更多细节的披露，业界将密切关注这一潜在合作对Tempest长期价值的影响。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TPST":"Tempest Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Tempest obtains exclusive licensing option for clinical-stage CD7-targeted lentivirus in vivo CAR-T platform","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":1},"content_text":"Tempest Therapeutics Inc.（TPST）近日宣布，已成功获得一项独家选择权，旨在许可一个处于临床阶段的、靶向CD7的慢病毒体内CAR-T平台。此举标志着该公司在细胞治疗领域迈出了关键一步，有望进一步增强其在肿瘤免疫疗法方面的布局。\n该平台依托慢病毒载体技术，能够实现体内CAR-T细胞的直接生成，从而可能简化传统体外细胞改造流程，并降低相关成本与复杂性。临床阶段的数据积累为平台的有效性与安全性提供了初步验证，尤其针对CD7阳性恶性肿瘤，如某些类型的白血病和淋巴瘤。\n根据协议条款，Tempest有权在特定条件下行使该选择权，以获取平台的全球独家开发和商业化权益。这一战略决策不仅丰富了公司的研发管线，也为探索联合疗法及新适应症开辟了可能性。\n市场分析人士指出，体内CAR-T技术是当前基因与细胞治疗领域的前沿方向，其便捷性和可扩展性备受期待。Tempest若能成功整合该平台，或将提升其在竞争激烈的肿瘤治疗市场中的地位。公司管理层表示，将对该平台进行进一步评估，并可能在未来启动相关临床试验。\n此次协议的达成，反映了Tempest致力于通过创新技术平台来应对未满足医疗需求的坚定承诺。随着更多细节的披露，业界将密切关注这一潜在合作对Tempest长期价值的影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}